Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) Revenue (2016 - 2025)

Vistagen Therapeutics' Revenue history spans 12 years, with the latest figure at $303000.0 for Q4 2025.

  • For Q4 2025, Revenue rose 29.49% year-over-year to $303000.0; the TTM value through Dec 2025 reached $790000.0, up 13.13%, while the annual FY2025 figure was $486000.0, 54.32% down from the prior year.
  • Revenue for Q4 2025 was $303000.0 at Vistagen Therapeutics, up from $258000.0 in the prior quarter.
  • Across five years, Revenue topped out at $441900.0 in Q1 2021 and bottomed at -$15000.0 in Q1 2025.
  • The 4-year median for Revenue is $258000.0 (2025), against an average of $259286.7.
  • The largest YoY upside for Revenue was 190.48% in 2025 against a maximum downside of 107.6% in 2025.
  • A 4-year view of Revenue shows it stood at $358000.0 in 2021, then increased by 14.8% to $411000.0 in 2023, then plummeted by 43.07% to $234000.0 in 2024, then rose by 29.49% to $303000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Revenue are $303000.0 (Q4 2025), $258000.0 (Q3 2025), and $244000.0 (Q2 2025).